Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse.

Aaron-Brooks LM, Sasaki T, Vickman RE, Wei L, Franco OE, Ji Y, Crawford SE, Hayward SW.

Prostate. 2019 Jun;79(9):980-993. doi: 10.1002/pros.23809. Epub 2019 Apr 18.

PMID:
30999385
2.

DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.

Nardi F, Franco OE, Fitchev P, Morales A, Vickman RE, Hayward SW, Crawford SE.

Sci Rep. 2019 Feb 28;9(1):3035. doi: 10.1038/s41598-019-39537-z.

3.

Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.

Sasaki T, Franco OE, Ohishi K, Filipovich Y, Ishii K, Crawford SE, Takahashi N, Katayama N, Sugimura Y, Hayward SW.

Prostate. 2019 Feb;79(3):259-264. doi: 10.1002/pros.23730. Epub 2018 Oct 28.

PMID:
30370673
4.

PEDF regulates plasticity of a novel lipid-MTOC axis in prostate cancer-associated fibroblasts.

Nardi F, Fitchev P, Franco OE, Ivanisevic J, Scheibler A, Hayward SW, Brendler CB, Welte MA, Crawford SE.

J Cell Sci. 2018 Jul 11;131(13). pii: jcs213579. doi: 10.1242/jcs.213579.

5.

Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin.

Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, Washington MK, Shi C, Franco OE, Weaver AM, Hayward SW, Li D, Webb DJ.

J Cell Biol. 2017 Nov 6;216(11):3799-3816. doi: 10.1083/jcb.201704053. Epub 2017 Oct 11.

6.

Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Sasaki T, Franco OE, Hayward SW.

Differentiation. 2017 Jul - Aug;96:40-48. doi: 10.1016/j.diff.2017.07.002. Epub 2017 Jul 20. Review.

7.

A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J.

Prostate. 2017 Aug;77(11):1213-1220. doi: 10.1002/pros.23380. Epub 2017 Jun 28.

8.

Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.

Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, Anbalagan A, Chen X, Mattingly RR, Hayward SW, Sloane BF.

Breast Cancer Res. 2017 May 15;19(1):56. doi: 10.1186/s13058-017-0847-0.

9.

Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts.

Nash C, Boufaied N, Mills IG, Franco OE, Hayward SW, Thomson AA.

Mol Cell Endocrinol. 2018 Aug 15;471:1-14. doi: 10.1016/j.mce.2017.05.006. Epub 2017 May 5.

PMID:
28483704
10.

Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo.

Yang S, Jiang M, Grabowska MM, Li J, Connelly ZM, Zhang J, Hayward SW, Cates JM, Han G, Yu X.

Oncotarget. 2016 Oct 25;7(43):70404-70419. doi: 10.18632/oncotarget.11879.

11.

Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90.

Henke A, Franco OE, Stewart GD, Riddick AC, Katz E, Hayward SW, Thomson AA.

Cancers (Basel). 2016 Aug 24;8(9). pii: E77. doi: 10.3390/cancers8090077.

12.

Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.

Aaron L, Franco OE, Hayward SW.

Urol Clin North Am. 2016 Aug;43(3):279-88. doi: 10.1016/j.ucl.2016.04.012. Review.

13.

Altered TGF-α/β signaling drives cooperation between breast cancer cell populations.

Franco OE, Tyson DR, Konvinse KC, Udyavar AR, Estrada L, Quaranta V, Crawford SE, Hayward SW.

FASEB J. 2016 Oct;30(10):3441-3452. Epub 2016 Jul 6.

14.

NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Aug;76(11):1004-18. doi: 10.1002/pros.23195. Epub 2016 May 16.

15.

Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Bianchi-Frias D, Basom R, Delrow JJ, Coleman IM, Dakhova O, Qu X, Fang M, Franco OE, Ericson NG, Bielas JH, Hayward SW, True L, Morrissey C, Brown L, Bhowmick NA, Rowley D, Ittmann M, Nelson PS.

Mol Cancer Res. 2016 Apr;14(4):374-84. doi: 10.1158/1541-7786.MCR-15-0330. Epub 2016 Jan 11.

16.

NF-κB and androgen receptor variant expression correlate with human BPH progression.

Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW.

Prostate. 2016 Apr;76(5):491-511. doi: 10.1002/pros.23140. Epub 2015 Dec 28.

17.

Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.

Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ.

Endocrinology. 2016 Mar;157(3):1094-109. doi: 10.1210/en.2015-1312. Epub 2015 Dec 17.

18.

Isolation and analysis of discreet human prostate cellular populations.

Strand DW, Aaron L, Henry G, Franco OE, Hayward SW.

Differentiation. 2016 Apr-Jun;91(4-5):139-51. doi: 10.1016/j.diff.2015.10.013. Epub 2015 Nov 3. Review.

19.

Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.

Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF.

BMC Cancer. 2015 Aug 13;15:584. doi: 10.1186/s12885-015-1576-3.

20.

Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expression.

Huynh TP, Barwe SP, Lee SJ, McSpadden R, Franco OE, Hayward SW, Damoiseaux R, Grubbs SS, Petrelli NJ, Rajasekaran AK.

PLoS One. 2015 Apr 2;10(4):e0122442. doi: 10.1371/journal.pone.0122442. eCollection 2015.

21.

Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.

Nolan KD, Franco OE, Hance MW, Hayward SW, Isaacs JS.

J Biol Chem. 2015 Mar 27;290(13):8271-82. doi: 10.1074/jbc.M115.637496. Epub 2015 Feb 10.

22.

Stretching fibroblasts remodels fibronectin and alters cancer cell migration.

Ao M, Brewer BM, Yang L, Franco Coronel OE, Hayward SW, Webb DJ, Li D.

Sci Rep. 2015 Feb 9;5:8334. doi: 10.1038/srep08334.

23.

Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.

Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ.

Oncogene. 2015 Jul;34(28):3700-10. doi: 10.1038/onc.2014.302. Epub 2014 Sep 15.

24.

SOX2 expression in the developing, adult, as well as, diseased prostate.

Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):301-9. doi: 10.1038/pcan.2014.29. Epub 2014 Aug 5.

25.

Stromal androgen receptor in prostate development and cancer.

Singh M, Jha R, Melamed J, Shapiro E, Hayward SW, Lee P.

Am J Pathol. 2014 Oct;184(10):2598-607. doi: 10.1016/j.ajpath.2014.06.022. Epub 2014 Aug 1. Review.

26.

Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.

Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Zhang MZ, Hayward SW, Love HD, Falck JR, Manthati VL, Imig JD, Schwartzman ML, Zent R, Capdevila JH, Pozzi A.

J Am Soc Nephrol. 2015 Mar;26(3):597-610. doi: 10.1681/ASN.2013090980. Epub 2014 Jul 28.

27.

FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype.

DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ.

Lab Invest. 2014 Jul;94(7):726-39. doi: 10.1038/labinvest.2014.64. Epub 2014 May 19.

28.

Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis.

San Martin R, Barron DA, Tuxhorn JA, Ressler SJ, Hayward SW, Shen X, Laucirica R, Wheeler TM, Gutierrez C, Ayala GE, Ittmann M, Rowley DR.

Am J Pathol. 2014 Jun;184(6):1860-70. doi: 10.1016/j.ajpath.2014.02.021. Epub 2014 Apr 5.

29.

F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder.

Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, Pope JC 4th, Adams MC, Brock JW 3rd, Clark PE, Hayward SW, Matusik RJ, Milne GL.

J Urol. 2014 May;191(5 Suppl):1597-601. doi: 10.1016/j.juro.2013.09.027. Epub 2014 Mar 26.

PMID:
24679873
30.

Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW.

Prostate. 2014 May;74(6):669-79. doi: 10.1002/pros.22785. Epub 2014 Feb 5.

31.

ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.

Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A.

Cancer Res. 2014 Mar 1;74(5):1404-15. doi: 10.1158/0008-5472.CAN-13-1296. Epub 2014 Jan 2.

32.

SPARCL1 suppresses metastasis in prostate cancer.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL Jr, Yi Y.

Mol Oncol. 2013 Dec;7(6):1019-30. doi: 10.1016/j.molonc.2013.07.008. Epub 2013 Jul 20.

33.

A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells.

Moad M, Pal D, Hepburn AC, Williamson SC, Wilson L, Lako M, Armstrong L, Hayward SW, Franco OE, Cates JM, Fordham SE, Przyborski S, Carr-Wilkinson J, Robson CN, Heer R.

Eur Urol. 2013 Nov;64(5):753-61. doi: 10.1016/j.eururo.2013.03.054. Epub 2013 Apr 6.

34.

Chronic cyclic bladder over distention up-regulates hypoxia dependent pathways.

Stephany HA, Strand DW, Ching CB, Tanaka ST, Milne GL, Cajaiba MM, Thomas JC, Pope JC 4th, Adams MC, Brock JW 3rd, Hayward SW, Matusik RJ, Clayton DB.

J Urol. 2013 Oct;190(4 Suppl):1603-9. doi: 10.1016/j.juro.2013.02.026. Epub 2013 Feb 19.

35.

Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration.

Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW.

Am J Pathol. 2013 Feb;182(2):449-59. doi: 10.1016/j.ajpath.2012.10.007. Epub 2012 Dec 6.

36.

Reduction of pro-tumorigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1.

Orr B, Grace OC, Brown P, Riddick AC, Stewart GD, Franco OE, Hayward SW, Thomson AA.

Dis Model Mech. 2013 Mar;6(2):530-6. doi: 10.1242/dmm.010355. Epub 2012 Nov 7.

37.

Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium.

Pruitt FL, He Y, Franco OE, Jiang M, Cates JM, Hayward SW.

Prostate. 2013 Apr;73(5):476-88. doi: 10.1002/pros.22589. Epub 2012 Sep 19.

38.

Targeting the tumor stroma as a novel therapeutic approach for prostate cancer.

Franco OE, Hayward SW.

Adv Pharmacol. 2012;65:267-313. doi: 10.1016/B978-0-12-397927-8.00009-9. Review.

PMID:
22959029
39.

PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation.

Strand DW, Jiang M, Murphy TA, Yi Y, Konvinse KC, Franco OE, Wang Y, Young JD, Hayward SW.

Cell Death Dis. 2012 Aug 9;3:e361. doi: 10.1038/cddis.2012.99.

40.

The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.

Wang H, Jiang M, Cui H, Chen M, Buttyan R, Hayward SW, Hai T, Wang Z, Yan C.

Mol Cell Biol. 2012 Aug;32(16):3190-202. doi: 10.1128/MCB.00159-12. Epub 2012 Jun 4.

41.

Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.

Ricke EA, Williams K, Lee YF, Couto S, Wang Y, Hayward SW, Cunha GR, Ricke WA.

Carcinogenesis. 2012 Jul;33(7):1391-8. doi: 10.1093/carcin/bgs153. Epub 2012 Apr 25.

42.

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis.

Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, Doubinskaia I, van der Meer R, Hayward SW, Eischen CM, Eltoum IE, Abdulkadir SA.

J Clin Invest. 2012 May;122(5):1907-19. doi: 10.1172/JCI58540. Epub 2012 Apr 9.

43.

Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.

Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA.

Mol Cancer Res. 2012 Apr;10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506. Epub 2012 Jan 30.

44.

Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game.

Basanta D, Scott JG, Fishman MN, Ayala G, Hayward SW, Anderson AR.

Br J Cancer. 2012 Jan 3;106(1):174-81. doi: 10.1038/bjc.2011.517. Epub 2011 Dec 1.

45.

Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate.

Orr B, Riddick AC, Stewart GD, Anderson RA, Franco OE, Hayward SW, Thomson AA.

Oncogene. 2012 Mar 1;31(9):1130-42. doi: 10.1038/onc.2011.312. Epub 2011 Aug 1.

46.

PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW.

Differentiation. 2011 Nov-Dec;82(4-5):220-36. doi: 10.1016/j.diff.2011.05.008. Epub 2011 Jun 8. Review.

47.

Spontaneous immortalization of human dermal microvascular endothelial cells.

Jiang M, Min Y, Debusk L, Fernandez S, Strand DW, Hayward SW, Lin PC.

World J Stem Cells. 2010 Oct 26;2(5):114-20. doi: 10.4252/wjsc.v2.i5.114.

48.

Role for stromal heterogeneity in prostate tumorigenesis.

Kiskowski MA, Jackson RS 2nd, Banerjee J, Li X, Kang M, Iturregui JM, Franco OE, Hayward SW, Bhowmick NA.

Cancer Res. 2011 May 15;71(10):3459-70. doi: 10.1158/0008-5472.CAN-10-2999. Epub 2011 Mar 28.

49.

Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis.

Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS 2nd, Revelo MP, Bhowmick NA, Hayward SW.

Cancer Res. 2011 Feb 15;71(4):1272-81. doi: 10.1158/0008-5472.CAN-10-3142. Epub 2011 Feb 8.

50.

E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.

Sun H, Wang Y, Chinnam M, Zhang X, Hayward SW, Foster BA, Nikitin AY, Wills M, Goodrich DW.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):704-9. doi: 10.1073/pnas.1015027108. Epub 2010 Dec 27.

Supplemental Content

Loading ...
Support Center